IonDX Appoints Life Sciences Industry Leader Luis Carbonell as Chief Executive Officer
Monterey, CA, Dec 18, 2023: IonDX, a life sciences instrumentation company, is pleased to announce the
appointment of Mr. Luis Carbonell as its new Chief Executive Officer, effective immediately.
Mr. Carbonell is a seasoned life sciences industry executive with a broad range of experiences
encompassing research tools, clinical diagnostics, and pharmaceuticals. He has navigated small companies through their earliest stages (pre-incorporation and seedfunding), as well as led large international expansion projects for multi-billion-dollar corporations. He steered MagArray (a Stanford University spinout) through the commercialization of a lung cancer diagnostic test based on its proprietary magneto-biosensor
technology. He guided BioStinger (a UC Santa Cruz spinout) through the commercial development of a novel nanopipette technology for single cell analysis.
“I am honored to join such a talented team. IonDX has developed amazing applications for ion mobility that
are poised to make a significant impact in the life sciences field, and I am excited to become a part of it.”, said Mr. Luis Carbonell.
“IonDX has been a small R&D company and with Mr. Carbonell’s leadership we will become a
full-fledged scientific instrument company. Just watch.” said Dr. Henry Benner, Founder of IonDX.
With an impressive track record of taking early-stage companies through successful growth stages, Mr.
Carbonell’s expertise will undoubtedly help IonDX reach an era of new achievements.
IonDX is an early-stage instrumentation company that is developing innovative analytical tools and
workflows to accelerate drug discovery. The company is revolutionizing ion-mobility based screening and structural understanding of biological drugs.
For media inquiries or more information about IonDX, please contact:
Ananya Dubey Kelsoe
Vice President, Business and Strategy
New Nature article mentions IonDXTM Inc.'s patented Soft Landing Device
Monterey,CA, October 16, 2023: IonDX's patented Soft Landing Device was mentioned in the Nature Technology Feature article. The article, entitled "Soft-Landing Methods Aim to Simplify Structural Biology", discusses sample preparation hurdles when applying intact proteins to grids prior to analysis by cryo-electron microscopy (cryo-EM), and recent technology developments that may help bridge that gap.
Link to the Nature article: Nature 2023 article_SLD.pdf (strikinglycdn.com)
Genentech and IonDXTM co-author mAbs Journal article
Monterey, CA, October 25, 2022: Insights into ultra-low affinity lipase-antibody noncovalent complex binding mechanisms
Elizabeth Sara Hecht, Shrenik Mehta, Aaron T. Wecksler, Ben Aguilar, Nathaniel Swanson, Wilson Phung, Ananya Dubey Kelsoe, W. Henry Benner, Devin Tesar, Robert F. Kelley, Wendy Sandoval & Alavattam Sreedhara
mAbs, Volume 14, Issue 1 (2022)
Link to the mAbs Journal article: tandfonline.com/doi/pdf/10.1080/19420862.2022.2135183?needAccess=true
IonDX™ Starts An Early Access Program
Monterey, CA, April 1,2021: IonDX Inc.™ Inc., a lifesciences instrumentation company, has initiated an Early Access Program in support of launching their first product, the IMGenius™ system, at ASMS 2021. IonDX is focused on developing biotherapeutic analytical solutions to support accelerated drug development.
“The Early Access Program is a structured product introduction aimed at select biopharma industry customers prior to the official launch. This pre-commercial engagement process will ensure the long-term success of IMGenius”, said Ms. Ananya Dubey Kelsoe, Executive Director of Business and Corporate Development at IonDX.
IonDX’s technology is atmospheric pressure ion mobility spectrometry that analyzes biologically relevant native conformations of proteins, protein complexes and nucleic acid modalities. The company is currently involved in several industry-wide collaborations (confidentiality agreements prevent disclosure). IonDX is planning to launch its first bench-top spectrometer in Q3 of this year and is currently engaging with key technology adopters.
For more information on the Early Access Program or to learn more about the IMGenius system, please contact:
GlycoSeLect and IonDx Inc., Collaborating on High-throughput Glycoprotein Analyses
Monterey, CA, USA and Dublin Ireland ‐ November 16, 2020 – GlycoSeLect Ltd and IonDx Inc. are actively engaged in a research collaboration to evaluate the use of Recombinant Prokaryotic Lectins (RPLs) and IonDx’s Ion Mobility Spectrometry technology as a new way to screen glycoproteins rapidly.
“GlycoSeLect’s glycan specific lectins provide a high degree of specificity that will improve detection, monitoring and profiling of glycosylation within a wide range of biotherapeutics. Hence, we are excited to join GlycoSeLect and apply our ion mobility technology to all phases of biotherapeutic production and help manufacturers streamline this analytical bottleneck”, said Ms. Ananya Dubey Kelsoe, Executive Director of Business and Corporate Development at IonDx Inc.
Robert Dunne, GlycoSeLect CEO commented that “The GlycoSeLect team is pleased to work with our friends in IonDx. Our RPL technology has been shown to be highly specific in detecting glycan structures which is vital for the analysis of biotherapeutic products. The IonDx team has developed impressive ion mobility technology and applications potential for fast routine batch to batch screening or clone selection. The combination of our technologies bodes well for developing a more efficient workflow for biotherapeutic analytics”.
About GlycoSelect Ltd
GlycoSeLect Ltd develops innovative technologies for the analysis, characterisation and purification of biopharmaceuticals. These next-generation products are highly specific for glycan structures improving product development and improving the cost-efficiency of their manufacturing. GlycoSeLect specialises in the development of proteins based on recombinant prokaryotic lectins RPLs. Our RPL products advance efficient detection, analysis and selective isolation of glycosylated pharmaceutical products. GlycoSeLect’s family of RPLs products are associated with market-leading properties, including high affinity for glycan targets, high sensitivity of detection, high stability and robustness in process development.
About IonDX Inc.
IonDx Inc. is an early stage Life Sciences instrumentation company that is focused on developing biotherapeutic analytical solutions to support accelerated drug development. The company is planning to launch its first spectrometer in Q3’ 2021 and is currently engaging with interested technology adopters. IonDx’s core technology is atmospheric pressure ion mobility spectrometry that quantifies the biologically relevant conformations (native structures) of proteins and protein complexes.
Please contact Robert Dunne at firstname.lastname@example.org or +353 87 7902652.
Please visit www.iondx.com and send questions at email@example.com
IonDx Receives another National Science Foundation Award
August 18, 2020: National Science Foundation (NSF) awarded IonDx Inc., a Monterey, CA-based lifesciences instrumentation company the Technology Enhancement for Commercialization Partnerships (TECP) supplemental fund to their existing SBIR Phase-II grant on “Ion Mobility Spectrometer for Macromolecular Analysis”. This additional award will help IonDx with their commercialization and business development efforts.
“Our ion mobility technology is continually finding new application areas and this funding will help us move into gene therapy and biotherapeutics process control,” said Dr. Henry Benner, IonDx’s CEO and Founder
“We are quite excited with NSF’s continuing support of IonDx. This TECP fund will enable us to advance our B2C and B2B engagements that are important for the long-term commercial success of our technology” said Ananya Dubey Kelsoe, Executive Director of Business and Corporate Development at IonDx.
Link to the SBIR Phase-II Award: https://nsf.gov/awardsearch/showAward?AWD_ID=1926636